SERODUS ASA: MANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS (Serodus ASA)
(Source: Serodus ASA) Oslo, October 27, 2014: Serodus ASA (Oslo Axess: SER), the following transactions has today been exercised: Eva Steiness (CEO) has exercised 15 000...
View ArticleMANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS (Serodus ASA)
(Source: Serodus ASA) Oslo, December 10, 2015: Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 125 000 shares at an average price of NOK 2,1495 per...
View ArticleResults of Serodus’ SER140 in diabetic mice will be published in the Journal...
(Source: Serodus ASA) Oslo, Norway, 12 January 2016: Serodus ASA (SER) (Oslo Axess) today announced that the manuscript 'The IL-1b receptor antagonist SER140 postpones the onset of diabetes in female...
View ArticleWe are delighted to announce that Anthony Rosenberg has joined SERODUS ASA as...
(Source: Serodus ASA) Oslo, Norway, 19. January 2016: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces, that...
View ArticleSERODUS with successful presentations during JP Morgan Conference (Serodus ASA)
(Source: Serodus ASA) San Francisco, USA, 15. January 2016: Serodus ASA (Oslo Axess: SER) participated in the JP Morgan conference and presented the company and its drug candidates to numerous...
View ArticleQ3-2015 Interims results (Serodus ASA)
(Source: Serodus ASA) Oslo, 27. October 2015. Serodus ASA (OAX:SER) announces its results for the third quarter 2015. Highlights include: SER150 Diabetic Nephropathy Patients are being randomized to...
View ArticleQ2-2015 results (Serodus ASA)
(Source: Serodus ASA) Highlights include: First patients randomized in Phase IIa study in Diabetic Nephropathy (SER150) Phase I enabling studies completed successfully (SER130) Delays development of...
View ArticleSerodus ASA announces Q1 2015 results (Serodus ASA)
(Source: Serodus ASA) Oslo, 24. April 2015. Serodus ASA (OAX:SER) announces its results for the first quarter 2015. Highlights include: Identified a new indication for SER100...
View ArticleQ4-2015 Interim results (Serodus ASA)
(Source: Serodus ASA) Oslo, 17. February 2016. Serodus ASA (OAX:SER) announces its results for the fourth quarter 2015. Highlights include: SER150 Diabetic Nephropathy Completed patient randomization...
View ArticleSERODUS ASA appoints scientific advisors for development program in Acute...
(Source: Serodus ASA) Oslo, Norway, 17 December 2015: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the...
View ArticleSERODUS ASA presented at the DNB Healthcare conference in Oslo (Serodus ASA)
(Source: Serodus ASA) Oslo, 16 December, 2015: Serodus ASA (Oslo Axess: SER) presented the company and its drug candidates at the DNB Healthcare conference in Oslo. The presentation is available on...
View ArticleSERODUS ASA appoints scientific advisors for development program in diabetic...
(Source: Serodus ASA) Oslo, Norway, 09 December 2015: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the...
View ArticleFact Sheet (Serodus ASA)
(Source: Serodus ASA) FOCUS Therapeutic products in Cardiovascular diseases and Diabetes Partnerships Founded 2008 Public 2013 MANAGEMENT Eva Steiness Chief Executive Officer Tore Kvam Chief Financial...
View ArticleSerodus announces randomization of first patients in Phase IIa clinical trial...
(Source: Serodus ASA) The Phase IIa, safety and tolerability trial is expected to enroll up to total 76 patients, randomized in a 2:1 ratio to either SER150 or placebo treatment. The primary endpoint...
View ArticleSERODUS ASA appoints scientific advisors for development program in Type 2...
(Source: Serodus ASA) Oslo, Norway, 11 January 2016: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the...
View ArticlePeter Holm Tygesen joins Norwegian biotech company (Serodus ASA)
(Source: Serodus ASA) We are very pleased to bring Peter onboard the Serodus team. Peter has an impressive background with a broad know how of the drug manufacturing in the pharmaceutical industry. He...
View ArticleSerodus announces completion of patient enrollment of the first cohort in...
(Source: Serodus ASA) Oslo, February 3, 2016: Serodus (Oslo Axess: SER), today announced that the last patient in the first cohort was randomized into the SER150 multi-center, double-blind, randomized,...
View ArticleSERODUS ASA to present at the BIO Europe 2015 in Munich November 2-4 (Serodus...
(Source: Serodus ASA) Oslo, 03 November, 2015: Serodus ASA (Oslo Axess: SER) will present the company and its drug candidates at the BIO Europe 2015 in Munich. The company presentation will highlight...
View ArticleSERODUS ASA: CLINICAL TRIAL APPLICATION FILED FOR SER150 DIABETIC NEPHROPATHY...
(Source: Serodus ASA) "We are very pleased to reach this important milestone for our SER150 drug candidate and the study will be running during 2015 and 2016. Diabetic nephropathy is a severe...
View ArticleNikolai C. Brun joins Serodus (Serodus ASA)
(Source: Serodus ASA) We are very pleased to bring Nikolai onboard the Serodus team. He has an impressive background with a broad knowledge from drug development from previous work experience. He will...
View Article